NCT00426452View on ClinicalTrials.gov

A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 31, 2006

Conditions

Healthy

Interventions

DRUG

Vatalinib

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Novartis

INDUSTRY